Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study

Hum Vaccin Immunother. 2015;11(2):435-42. doi: 10.4161/21645515.2014.994460.

Abstract

The aim of this Phase IIIb, open-label, randomized study was to demonstrate the non-inferiority of immune responses and to assess the safety of a purified chick-embryo cell rabies vaccine (PCECV) in healthy Chinese children (6 to 17 years) and older adults (≥51 years) following 2 alternative intramuscular (IM) simulated post-exposure prophylaxis (PEP) regimens: 4-dose Zagreb or 5-dose Essen regimen. Serum samples were collected prior to vaccination on Days 1 and 15 and on day 43 to assess immune response by rabies virus neutralizing antibody (RVNA) concentrations. Solicited adverse events (AEs) were recorded for up to 7 days following each vaccine dose, and unsolicited AEs throughout the entire study period. PCECV vaccination induced a strong immune response at Day 15, and the non-inferiority in immune response of the Zagreb vs. the Essen regimen was demonstrated in children and older adults. At Day 15,100% of children (N = 224), and 99% of subjects ≥51 years of age (N = 376) developed adequate RVNA concentrations (≥0.5 IU/mL); at Day 43 all subjects achieved RVNA concentrations ≥0.5 IU/mL, for both PEP regimens. The well-known tolerability and safety profile of the PCECV was again observed in this study following either Zagreb or Essen regimens. Rabies PEP vaccination with PCECV following a Zagreb regimen induced immune responses non-inferior to those of the Essen regimen, and had a similar safety and tolerability profile to the Essen regimen in Chinese children, adolescents, and adults over 51 years. ClinicalTrials.gov identifier: NCT01680016.

Keywords: AE, adverse event; CI, confidence interval; Essen regimen; GMC, geometric mean concentration; IM, intramuscular; NIFDC, National Institutes for Food and Drug Control; PCECV, purified chick-embryo cell rabies vaccine; PEP, post-exposure prophylaxis; PPS, per-protocol set; RFFIT, Rapid Fluorescent Focus Inhibition Test; RVNA, rabies virus neutralizing antibody; Zagreb regimen; immunogenicity; intramuscular post-exposure prophylaxis; purified chick-embryo cell rabies vaccine; rabies; rabies virus neutralizing antibody.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Aged
  • Aged, 80 and over
  • Animals
  • Antibodies, Neutralizing / blood*
  • Antibodies, Viral / blood*
  • Chick Embryo
  • Child
  • China
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Post-Exposure Prophylaxis / methods*
  • Rabies / prevention & control*
  • Rabies Vaccines / administration & dosage
  • Rabies Vaccines / adverse effects*
  • Rabies Vaccines / immunology*
  • Rabies Vaccines / isolation & purification
  • Time Factors
  • Vaccination / methods*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Rabies Vaccines

Associated data

  • ClinicalTrials.gov/NCT01680016